Yahoo Web Search

Search results

1. • 

     Drug targeting clear cell renal cell carcinoma shows promising approach

     Newswise· 2 days ago

     April 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...

2. • Signs and Symptoms of Kidney Cancer

     Health via Yahoo News· 7 days ago

     What does the kidney cancer testing process look like? If I receive a diagnosis of kidney cancer, what treatment options are available? What symptoms would mean that my cancer ...

3. • 

     Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?

     Investor's Business Daily· 21 hours ago

     Overall, 27.3% responded to the treatment. A total of 63.6% of patients had their disease under...

4. • Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting

     WKBN 27 Youngstown· 14 hours ago

     First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study. First-in-class PD-1/IL-2 bispecific ...

5. • Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

     Morningstar· 14 hours ago

     The NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational...

6. • Small Business - Cordele Dispatch | Cordele Dispatch

     Cordele Dispatch· 1 day ago

     New York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected

7. • Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

     ETF DAILY NEWS· 11 hours ago

     Mirae Asset Global Investments Co. Ltd. grew its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the ...

8. • Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

     Morningstar· 3 days ago

     Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...

9. • 

     How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

     Zacks via Yahoo Finance· 3 days ago

     Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...

10. • Nisa Investment Advisors LLC Has $29,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

      ETF DAILY NEWS· 2 days ago

      Nisa Investment Advisors LLC lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 10,740.0% during the fourth quarter, according to its most recent 13F filing with ...